Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. (CRNX) has a dated report snapshot, but its current priced-in claim is temporarily suppressed because the live engine record is unavailable or has changed.
231 institutional managers reported holding CRNX in 13F filings for the quarter ended 2026-03-31. 40 opened new positions that quarter. Held by FMR (Fidelity), Vanguard Group, BlackRock, among others. On the short side, 12.9M shares were sold short as of the 2026-06-15 count, about 12% of shares outstanding (13.2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CRNX's share count grew 180.9% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at CRNX over the trailing three years. Absence is a fact about the company, not a signal. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CRNX's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-09 | -7.3% | +62.8% |
| 2023-11-08 | -6.7% | +32.2% |
| 2024-02-29 | +1.2% | +14.3% |
| 2024-05-10 | -5.7% | +11.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CRNX's latest 8-K filings: 2026-07-10 (items 1.01, 5.02); 2026-07-06 (items 1.01, 8.01, 9.01); 2026-06-22 (items 5.07); 2026-05-07 (items 2.02, 9.01); 2026-04-10 (items 5.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.